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Abstract
Background: Connexin26 (Cx26) is one of the connexins (Cxs) family members which form gap junction channels. 
Cx26 is considered to be a tumor suppressor gene. However, recent studies revealed that over expression of Cx26 is 
associated with a poor prognosis in several human cancers. This study investigated the correlation between Cx26 
expression and the clinicopathological features and P53 expression in colorectal cancer.
Methods: One hundred and fifty-three patients who underwent a curative resection were studied. Tissue samples 
were investigated by immunohistochemical staining using antibodies for Cx26 and P53. Moreover, apoptotic cells were 
detected by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) staining.
Results: Cx26 expression was found in 83 cases (54.2%) and P53 expression in 71 cases (46.4%). A correlation was 
observed between the Cx26 expression and recurrence, histology, and p53 expression (P < 0.05). Cx26 positive tumors 
had significantly longer survival than Cx26 negative tumors (P < 0.05). A multivariate Cox analysis demonstrated that 
Cx26 expression was an independent prognostic factor (P < 0.05). However, no significant correlation was observed 
between Cx26 and AI.
Conclusion: This study suggests that Cx26 expression is an independent prognostic factor in patients that undergo a 
curative resection of colorectal cancer.
Introduction
A gap junction is a specialized intercellular connection
that directly connects the cytoplasm of two cells, and
allows various molecules and ions ( < 1 kDa) to pass freely
between cells. Gap junctional intercellular communica-
tion (GJIC) mediated by gap junctions play an important
role in regulating homeostasis, proliferation and differen-
tiation [1,2]. Gap junction channels contain two hemi-
channels that are primarily homo -or hetero-hexamers of
connexin (Cx) proteins [3]. Twenty types of Cx have been
identified as transmembrane proteins [4]. A reduction or
loss of GJIC function associated with human carcinomas
such as skin cancer, lung cancer, gastric cancer, hepato-
cellular carcinoma, glioma and prostate cancer, is usually
induced by down-regulation of Cxs [5-9]. Moreover, res-
toration of GJIC in tumor cell lines by Cx transfection can
reduce growth and tumorigenicity [10,11]. Therefore, Cxs
are thought to be tumor suppressor genes. However, over
expression of Cx26 might the acquisition of malignant
phenotypes and is correlated with metastasis, tumor
grade and prognosis in several carcinomas [12-14].
Therefore, this study examined the correlation between
Cx26 expression by immunohistochemistry in colorectal
carcinoma and clinicopathological features and P53
expression as a tumor suppressor gene.
Materials and methods
This study evaluated 153 patients with colorectal carci-
noma who underwent a curative resection at the Depart-
ment of Surgical Oncology (First Department of Surgery)
of Osaka City University Graduate School of Medicine
(Osaka, Japan). The age of the patients ranged 30 from 84
years (mean 65.5 years); and there were 87 males and 66
females were included. All of them underwent a curative
resection and were followed for at least 5 years after sur-
gery. Hematoxylin and eosin-stained slides were reviewed
and the diagnoses were confirmed.
Tumor staging was defined according to the criteria for
histological classification proposed by the International
Union Against Cancer (UICC). Patients were informed of
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the investigational nature of the study and each provided
written informed consent prior to recruitment.
Resected specimens from these patients were fixed in a
10% formaldehyde solution and embedded in paraffin.
Four micrometer thick sections were cut and mounted on
glass slides.
Immunohistochemical method
Cx26 and P53 immunostaining were performed by the
streptavidin-biotin method. As primary antibodies,
mouse monoclonal anti-Cx26 (Zymed Laboratories, San
Francisco, CA, working dilution 1:500) and mouse mono-
clonal P53 antibodies (DAKO, Carpinteria, CA, ready to
use) were used. The sections were cut (4 μm), dried for 4
h at 58˚C, and then dewaxed in xylene and dehydrated
through an ethanol series. Endogenous peroxidase was
blocked by incubation with 0.3% H2O2 in methanol for
30 min at room temperature. Thereafter, the sections
were autoclaved for 10 min at 121˚C in 10 mM sodium
citrate (pH 6.0). The sections were washed with phos-
phate-buffered saline (PBS) and incubated with 10% nor-
mal rabbit serum for 10 min to reduce non-specific
staining. The specimens were incubated with the respec-
tive primary antibodies in a moist chamber overnight at
4°C. The specimens were washed with PBS and incubated
in a secondary antibody for 10 min at room temperature.
The sections were washed three times in PBS and incu-
bated with the streptavidin-peroxidase reagent for 5 min
at room temperature. Finally, the sections were incubated
for 5 min in PBS containing diaminobenzidine and 1%
hydrogen peroxide (Histofine SAB-PO kit, Nichirei), fol-
lowed by counterstaining with Mayer's hematoxylin. As
the negative control, incubation with the primary anti-
body was omitted.
Moreover, we investigated the apoptotic cells by termi-
nal deoxynucleotidyl transferase-mediated dUTP-biotin
nick end-labeling (TUNEL) staining, using an In Situ
Apoptosis Detection Kit (MK-500; Takara bio Co., Tokyo,
Japan) according to the manufacturer's instructions.
Staining Analysis
Immunoreactivity for Cx26 was considered to be positive
if distinct staining of the cytoplasm was observed in at
least 10% of the tumor cells (Fig. 1) and P53 was consid-
ered to be positive if distinct staining of the nuclei was
observed in at least 50% of tumor cells (Fig. 2). The apop-
totic index (AI) was expressed as the number of apoptotic
tumor cells divided by the total number of tumor cells in
the same field with evaluation of 1000 nuclei in randomly
selected areas in each specimen (Fig. 3).
The slides were examined by two independent patholo-
gists who were not aware of the corresponding clinico-
pathological data. Any cases with discordant scores were
reevaluated a second time until a consensus was reached,
no discrepancies between the evaluations were detected
by the two investigators.
Statistical Analysis
The data were compiled and analyzed using the SPSS
software package for Windows (version 11.0; SPSS Inc.,
Chicago, Ill., USA). The relationship between Cx26
expression and the clinicopathological data, P53 and AI
was evaluated by the chi-square test and Mann-Whitney
U test. The disease specific survival was calculated by the
Kaplan-Meier method and analyzed by the log-rank test.
Prognostic factors were examined by univariate and mul-
tivariate analyses using a Cox proportional hazards
model. P < 0.05 was considered to be significant.
Results
Cx26 expression was mainly localized in the cytoplasm of
the cancer cells. In a few cases, we observed weak cyto-
Figure 1 Immunohistochemical staing for Cx26 in colorectal can-
cer. Cytoplasmic Cx26 expression was found (×200).
Figure 2 Immunohistochemical staing for P53 in colorectal can-
cer. Nuclear P53 expression was found in most tumor cells (×200).Nomura et al. Journal of Experimental & Clinical Cancer Research 2010, 29:79
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plasmic staining in the normal mucosa. However we did
not consider this to be specific staining. Eighty-three of
the 153 tumors (54.2%) showed Cx26 expression. P53
expression was observed in 71 (46.4%). The correlation
between Cx26 and the clinicopathological features is
summarized in Table 1. Cx26 expression had a statisti-
cally significant relationship with disease recurrence and
the histological type (P < 0.05). Moreover P53 expression
had a statistically significant relationship with Cx26
expression (P < 0.05). The disease specific survival
according to the status of Cx26 expression is shown in
Fig.4. The patients with Cx26 negative tumors had signif-
icantly worse survival than those with positive tumors (P
< 0.05). Cx26 expression was an independent prognostic
factor, as well as lymph node metastasis, blood vessels
invasion according to a multivariate analysis (Table 2). Figure 3 Apoptotic index (AI) as evaluated by TUNEL (×200).
Table 1: Correlation between the Cx26 expression and clinicopathological features
Cx26
Negative Positive P-value
Age (mean ± SD, years. 66.4 ± 8.1 66.4 ± 10.5
Gender
Male 41 46
Female 29 37 0.695
Tumor size (mean ± SD, cm. 5.0 ± 2.1 5.1 ± 2.9
Lymphatic invasion
Negative 24 25
Positive 46 58 0.582
Blood vessel invasion
Negative 60 68
Positive 10 15 0.528
Lymph node metastasis
Negative 47 53
Positive 23 30 0.670
Site
Colon 47 60
Rectum 23 23 0.489
Depth of invasion
~mp 17 11
~ss 53 72 0.079
Disease recurrence
Negative 44 65
Positive 26 18 0.035
Histological type
Well 22 27
Moderately 37 55
Others 11 1 0.003
P53
Negative 31 51
Positive 39 32 0.034Nomura et al. Journal of Experimental & Clinical Cancer Research 2010, 29:79
http://www.jeccr.com/content/29/1/79
Page 4 of 6
There was no significant correlation between Cx26 and
AI (Fig. 5).
Discussion
Several studies of colorectal carcinoma reported that
Cx26 expression is found mainly in the plasma mem-
brane in normal epithelium and malignant transforma-
tion is associated with the loss of plasma membrane
staining and increased cytoplasmic staining [15-18].
However, Knösel et al. also reported the Cx26 expression
to be observed in the cytoplasm of colon cancer cells,
while it was not observed in the normal mucosa [19]. Our
current data showed the same results. The Cx26 expres-
sion was observed in the cytoplasm in 54.2% of the col-
orectal tumors in the current series. Although, the
mechanism of cytoplasmic staining was unclear, we
therefore assumed the cytoplasmic staining of Cx26 to be
independent from the GJIC- mechanism in colon cancer.
Several studies reported that Cx26 expression is associ-
ated with poor prognosis in lung and esophageal
squamous cell carcinoma and breast cancer [13,14,20].
However Knösel et al. [19] reported that reduced Cx26
expression is significantly associated with shorter
patients' survival and higher tumor grade. The current
study also found that patients with Cx26 negative tumors
had worse survival than those with Cx26 positive tumors.
Figure 4 The disease specific survival according to Cx26 expres-
sion. Patients with Cx26 positive tumors showed significantly longer 
survival than those with Cx26 negative tumors (P = 0.0128)
Table 2: Univariate and multivariate survival analyses of the prognostic factors
Multivariate analysis
Variable Comparsiion Hazard ratio P-value 95% CI
Cx26 Negative : Positive 3.734 0.002 1.607-8.674
Lymph node 
metastasis
Positive : Negative 2.587 0.027 1.115-5.999
Lymphatic invasion Positive : Negative 2.584 0.139 0.735-9.083
Vessel invasion Positive : Negative 4.084 0.002 1.687-9.887
Tumor size >5 cm : %5 cm 2.658 0.065 0.941-7.507
Univariate analysis
Cx26 Negative : Positive 2.651 0.017 1.191-5.903
Lymph node 
metastasis
Positive : Negative 4.720 <0.001 2.118-10.516
Lymphatic invasion Positive : Negative 4.387 0.016 1.320-14.580
Vessel invasion Positive : Negative 4.044 <0.001 1.844-8.870
Tumor size >5 cm : %5 cm 3.961 0.005 1.500-10.462
Figure 5 Value of apoptotic index (AI) according to Cx26 expres-
sion. No significant correlation was found (P = 0.273)Nomura et al. Journal of Experimental & Clinical Cancer Research 2010, 29:79
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Moreover, the multivariate analysis showed that Cx26
was an independent prognostic factor.
Cx26 is thought to be a tumor suppressor gene, but
mechanism which regulates tumor suppression is
unclear. Several studies have reported suggestive evi-
dence that the tumor-suppressive effects of Cx expression
are GJIC-independent [10,21]. Cytoplasmic staining of
Cx26 was considered to be a GJIC-independent mecha-
nism. Cx26 may have an effect on other tumor related
genes. Hong et al. reported a significant correlation
between the Cx26 expression and P53 expression [17].
P53 is a common tumor suppressor gene and plays a
major role in regulating the cell cycle and apoptosis [22].
The expression of P53 in colorectal cancer is thought to
be associated with poor prognosis [23-25]. A mutation of
the P53 is frequently observed in several human tumors.
The expression of P53 protein is equivalent to the pres-
ence of a mutation of the p53 gene [26]. Therefore, we
investigated the relationship between Cx26 and P53 pro-
tein. Cx26 expression had an inverse correlation with P53
expression. Cx26 positive tumors tended to have negative
P53 expression.
On the other hand, p53 gene regulates apoptosis and
P53 positive tumors show decreased AI [27]. Therefore,
the relationship between Cx26 and AI was investigated.
However, there was no significant relationship between
Cx26 and AI.
In conclusion, the Cx26 function in cancer cells is
unclear. Cx26 expression was an independent prognostic
factor in colorectal cancer in the current series. There-
fore, an analysis of the Cx26 expression may be useful for
selecting patients who are at high risk for recurrence.
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